Pyxis Oncology, Inc. announced dosing of the first subject in the Phase 1 trial of PYX-106. PYX-106 is a fully human immunotherapy antibody candidate that is designed to block the activity of Siglec-15, an immune suppressor expressed across a broad range of tumors. The Company also announced that the second dose level has been initiated in the ongoing Phase 1 trial of PYX-201, a novel antibody-drug conjugate (ADC) product candidate licensed from Pfizer targeting extradomain-B (EDB) of fibronectin, a non-internalizing antigen that is an integral component of the extracellular matrix in tumors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.17 USD | -0.95% | -7.54% | +131.67% |
May. 14 | Earnings Flash (PYXS) PYXIS ONCOLOGY Posts Q1 Revenue $16.1M | MT |
May. 14 | Pyxis Oncology, Inc. Appoints Stephen Worsley as its Senior Vice President | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+131.67% | 246M | |
+8.29% | 114B | |
+10.21% | 104B | |
-11.90% | 22.41B | |
+0.41% | 22.28B | |
-5.52% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- PYXS Stock
- News Pyxis Oncology, Inc.
- Pyxis Oncology, Inc. Advances Pyx-106 and PYX-201 Clinical Programs